DexCom (NASDAQ: DXCM) and Antares Pharma (NASDAQ:ATRS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.
This table compares DexCom and Antares Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for DexCom and Antares Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DexCom presently has a consensus price target of $67.44, indicating a potential upside of 17.62%. Antares Pharma has a consensus price target of $4.08, indicating a potential upside of 70.50%. Given Antares Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Antares Pharma is more favorable than DexCom.
Risk and Volatility
DexCom has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Insider & Institutional Ownership
34.7% of Antares Pharma shares are owned by institutional investors. 1.7% of DexCom shares are owned by company insiders. Comparatively, 11.6% of Antares Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares DexCom and Antares Pharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DexCom||$573.30 million||8.69||-$65.60 million||($0.57)||-100.60|
|Antares Pharma||$52.22 million||7.17||-$24.33 million||($0.11)||-21.73|
Antares Pharma has lower revenue, but higher earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Antares Pharma, indicating that it is currently the more affordable of the two stocks.
Antares Pharma beats DexCom on 9 of the 15 factors compared between the two stocks.
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
About Antares Pharma
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.